ChromaDex’s (CDXC) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of ChromaDex (NASDAQ:CDXC) in a report published on Monday morning,Benzinga reports. The firm currently has a $11.00 target price on the stock.

Several other research analysts have also recently issued reports on CDXC. StockNews.com cut ChromaDex from a “strong-buy” rating to a “buy” rating in a research note on Thursday, March 6th. LADENBURG THALM/SH SH increased their price target on ChromaDex from $6.80 to $8.10 and gave the stock a “buy” rating in a research report on Wednesday, March 5th.

ChromaDex Price Performance

Shares of CDXC opened at $7.87 on Monday. The firm has a market capitalization of $611.50 million, a price-to-earnings ratio of 787.29 and a beta of 2.21. The company has a 50-day moving average of $6.16 and a 200 day moving average of $5.44. ChromaDex has a 1-year low of $2.31 and a 1-year high of $9.18.

Institutional Trading of ChromaDex

A number of hedge funds have recently bought and sold shares of the stock. USA Financial Formulas purchased a new position in shares of ChromaDex in the 4th quarter valued at $25,000. State of Wyoming bought a new stake in ChromaDex during the fourth quarter valued at about $39,000. Mercer Global Advisors Inc. ADV purchased a new position in ChromaDex in the fourth quarter valued at about $53,000. Truist Financial Corp bought a new position in ChromaDex in the fourth quarter worth about $54,000. Finally, FMR LLC bought a new position in ChromaDex in the third quarter worth about $55,000. Hedge funds and other institutional investors own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.